Loading clinical trials...
Loading clinical trials...
A Randomised, Single-blind, Placebo-controlled, Dose-escalation Study to Assess the Safety and Tolerability of Single and Repeat, Inhaled Doses of PC786 in Healthy Subjects Combined With a Randomised, Single-blind, Placebo-controlled, Parallel Group to Assess the Safety and Tolerability of a Single Dose of Inhaled PC786 in Subjects With Mild Asthma
Conditions
Interventions
PC786 - Single doses
Placebo - Single doses
+2 more
Locations
1
United Kingdom
Hammersmith Medicines Research
London, United Kingdom
Start Date
June 21, 2017
Primary Completion Date
December 15, 2017
Completion Date
December 15, 2017
Last Updated
December 21, 2017
NCT05045612
NCT06998251
NCT06521944
NCT07249320
NCT04896853
NCT03756766
Lead Sponsor
Pulmocide Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions